Jiangsu Nhwa Pharmaceutical Co., Ltd

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Jiangsu Nhwa Pharmaceutical Co., LTD

46 YRS

Jiangsu, China

CNY 1080 Million

599400 m²

Over 1000 people

Main Products: Buspirone Hydrochloride / Lithium Carbonate / Penfluridol / 1-{2-[(2,4-Dichlorobenzyl)Oxy]-2-(2,4-Dichlorophenyl)Ethyl}-1H-Imidazole / Econazole Nitrate / 1-[Phenyl-(4-Phenylphenyl)Methyl]Imidazole / Fenofibrate

Jiangsu, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

Manufacturer

Total Employees

1000+ People

Plant Size

900 Acres

Total Annual Revenue

CNY 123 Million

Production Experience

46+ Years

MAIN
PRODUCTS

1/3

Buspirone Hydrochloride

CAS: 33386-08-2

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

1/3

Lithium Carbonate

CAS: 554-13-2

Packing: 25 KG/Fibre Drum; 25 KG/Paper Bag; 25 KG/Woven Bag

Lead Time: 14-30 days

Inquiry

1/3

Penfluridol

CAS: 26864-56-2

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

ABOUT US

Jiangsu Nhwa Pharmaceutical Co., LTD

Jiangsu Enhua Pharmaceutical Co., Ltd., founded in 1978 and listed on Shenzhen Stock Exchange in 2008 with stock code 002262, is a pharmaceutical enterprise integrating science, industry and trade, a national designated manufacturer of psychotropic drugs, a national high-tech enterprise, a national top 100 pharmaceutical enterprises, a national technological innovation demonstration enterprise and a national intellectual property demonstration unit, The star unit of the national "20 years and 20 stars" pharmaceutical quality management enterprise, the enterprise confirmed by the international environmental certification (ISO14000), the first batch of innovative enterprises in Jiangsu Province, the vice president unit of China narcotic drugs Association and the vice president unit of Jiangsu Pharmaceutical Industry Association. The company mainly produces and operates central nervous system drugs, strategically positioned in the market of central nervous system drugs, and is mainly engaged in the development, production and sales of central nervous system drugs. It is an enterprise focusing on the subdivided market of central nervous system drugs, mainly including anesthesia, psychosis and neurology. Through years of unremitting efforts in product R & D, production and service, The company has established a complete product series and marketing network of central nervous system drugs, and strive to build an important manufacturer and distributor of central nervous system drugs in China. In addition, the company has a series of cardiovascular and cerebrovascular products in different R & D stages, with brand-new chemical structure and action mechanism, and gradually intervene in the cardiovascular and cerebrovascular drug market with broad market prospects.